Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes

BACKGROUND: The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin‐9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Am Heart Assoc
Prif Awduron: Gencer, Baris, Koskinas, Konstantinos C., Räber, Lorenz, Karagiannis, Alexios, Nanchen, David, Auer, Reto, Carballo, David, Carballo, Sebastian, Klingenberg, Roland, Heg, Dik, Matter, Christian M., Lüscher, Thomas F., Rodondi, Nicolas, Mach, François, Windecker, Stephan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2017
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5721754/
https://ncbi.nlm.nih.gov/pubmed/29122809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006537
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg